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Pharmaceutical controls are time-consuming and require extensive sample prepara-
tion. Process analytical technology (PAT) implementation in the pharmaceutical indus-
try would reduce these time consuming operations. To perform this implementation, the
use of analytical techniques capable of providing accurate results in a simple and rapid
manner is necessary (1). Other advantages include little or no sample preparation (2, 3).
Near infrared spectrophotometry (NIR) is a non-destructive and non-invasive technique
that allows determination of chemical properties such as active pharmaceutical ingredi-
ent (API) or excipient content.
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The paper proposes a near infrared method able to direct-
ly and simultaneously quantify ascorbic acid and sodium
ascorbate in powder blends for tableting and in vitamin
C chewable tablets without any sample preparation. In
the first step, calibration models for the quantification of
ascorbic acid and sodium ascorbate in powder blends
for tableting and subsequently in chewable vitamin C
tablets (corresponding to 80–120 % active substance)
were developed according to an experimental design
with 2 variables and 5 levels. Then, using the best cali-
bration models, the methods were fully validated in
terms of recovery, precision and accuracy for both pow-
der blends and vitamin C chewable tablets. The valida-
ted concentration range was 15.14–18.51 % for ascorbic
acid and 12.06–14.49 % for sodium ascorbate in powder
blends and 91.85–111.03 mg per tablet for ascorbic acid
and 71.01–84.50 mg per tablet for sodium ascorbate in
tablets. Validation results showed good precision and ac-
curacy.
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NIR spectroscopy can be used to perform quantitative determinations of one, two
or more compounds in complex matrices like, for instance, a pharmaceutical powder
blend for tableting or tablets. A NIR assay method is usually not developed in the »tra-
ditional« way as UV spectrometry or HPLC assay methods (4). A major step to develop
a NIR assay method is the calibration procedure for model development. Once calibra-
tion is developed and favourable predictions are expected, they must be validated to be
accepted for routine use. For external validation, independent sets of samples are need-
ed. There are several validation parameters that must be determined in order to be con-
sistent with the recommendations of official guidelines: accuracy, precision (repeatabili-
ty and intermediate precision), specificity, linearity and range of application (5, 6).
Many papers report the determination of API content in powder blends or tablets
by NIR methods (6, 7), but only a few are focused on the prediction of two or more APIs
and/or excipients combined in powder blends or tablets (8, 9).
The methods currently used to determine the amount of ascorbic acid and sodium
ascorbate in tablets or powder blends for tableting are HPLC (10, 11) and titrimetry (12,
13), but they have the disadvantage of being rather time-consuming. Unlike the conven-
tional methods, NIR-chemometric methods are faster and do not require prior prepara-
tion of the sample, so they can be a viable alternative for direct quantification of ascorbic
acid and sodium ascorbate in powder blends for tableting and vitamin C tablets. The
first objective of our research was to develop a NIR-chemometric method suitable for di-
rect quantification of both APIs from powder blends for tableting.
EXPERIMENTAL
Materials
Ascorbic acid and sodium ascorbate (NPCP, China), sorbitol and mannitol (Roquet-
te, France), orange flavour (Esarom, Romania), sodium saccharin (Niutang Chemical,
China), sodium cyclamate (Golden Time Enterprise, China), silicon dioxide – Aerosil
(RohmPharma Polymers, Germany) and magnesium stearate (Mosselman, Belgium)
were used.
Sample preparation
For calibration purposes, powder blends for vitamin C chewable tablets were pre-
pared. Ascorbic acid, sodium ascorbate, sorbitol, mannitol, sodium saccharin, sodium
cyclamate, orange flavour and silicon dioxide were mixed for 5 minutes using a plane-
tary mixer (PRS type, Erweka, Germany) and then passed through a 0.800-mm sieve.
Magnesium stearate was then added and mixing was continued for one more minute.
The mixture composition was designed for a tablet of a total mass of approximately 600
mg and for 180 mg vitamin C (consisting of 50 % ascorbic acid and 50 % sodium ascor-
bate in the tablet). This formulation will be further considered as the 100 % active con-
tent formulation. Quantitative and qualitative composition of vitamin C chewable tab-
lets are presented in Table I.
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Calibration and validation protocol
The calibration set used included 28 different formulations corresponding to 80, 90,
100, 110 and 120 % ascorbic acid and sodium ascorbate. The samples were prepared ac-
cording to an experimental design with two factors and 5 levels (Table II) on different
days, in the run order. This protocol included batches and days as sources of variability
for calibration steps.
To validate the NIR methods for the assay of ascorbic acid and sodium ascorbate,
the same formulations as for the calibration set, corresponding to 90, 100 and 110 % as-
corbic acid and sodium ascorbate (Table II, samples N7, N13 and N19), were manufac-
tured. At each of the three concentration levels four replicate samples were prepared. In
order to include batches and days as sources of variability in validation steps, this proto-
col was repeated three times on three different days, resulting in a total of 36 validation
samples.
NIR spectra recording
Powder blends for tableting were analyzed in a reflection mode using a FT-NIR ana-
lyzer (Antaris II, ThermoElectronScientific, USA) equipped with a sample cup spinner
for inhomogenous samples, an integrating sphere and an indium gallium arsenide
(InGaAs) detector. Reflection spectra were collected with OMNIC software (Thermo Sci-
entific, USA). Each spectrum was the average of 32 scans and the resolution was 8 cm–1
over a range from 11000 to 4000 cm–1. Each powder sample was analyzed three times.
From each sample, fifteen different intact tablets were analyzed in reflection mode
using the same FT-NIR analyzer equipped with a universal tablet holder.
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Table I. Composition of calibration and validation samples
Content (%) 80a 90a,b 100a,b 110a,b 120a
Vitamin C chewable tablet composition (mg per tablet)
Ascorbic Acid 97 % 82.4 92.7 103.0 113.3 123.6
Sodium ascorbate 72.0 81.0 90.0 99.0 108.0
Sorbitol 341.8 322.5 303.2 283.9 264.6
Mannitol 90.0 90.0 90.0 90.0 90.0
Orange flavour 1.5 1.5 1.5 1.5 1.5
Sodium saccharin 0.3 0.3 0.3 0.3 0.3
Sodium cyclamate 3.0 3.0 3.0 3.0 3.0
Silicon dioxide 3.0 3.0 3.0 3.0 3.0
Magnesium stearate 6.0 6.0 6.0 6.0 6.0
Tablet mass (mg) 600 600 600 600 600
a Calibration samples: levels 1-2-3-4-5.
b Validation samples: levels 2-3-4.
Spectral data analysis
Development of NIR calibration models is an iterative process and consists of che-
cking different spectral pretreatments, as well as their combinations within different
spectral ranges. Both the specific spectral regions containing strong bands or the whole
spectral range and different spectral pretreatments were tested in order to develop cali-
bration models for ascorbic acid and sodium ascorbate assay in powder blends for ta-
bleting and tablets. Development of models was based on the following spectral pre-
treatments: constant offset elimination (COE), straight line subtraction (SLS), standard
normal variate (SNV), minim-maxim normalization (MMN), multiplicative scatter cor-
rection (MSC), first-derivative (FD), second-derivative (SD) or combined methods: FD
followed by SLS, FD followed by SNV, FD followed by MSC.
The QUANT package of the OPUS 6.5 software package was used for multivariate
regressions, with no spectra pretreatment and after applying pre-processing methods.
This software allows model validation by full cross-validation and test-validation. For
the development of prediction models, the PLS (partial least squares) regression method
was used. The models for ascorbic acid and sodium ascorbate assay in powder blends
were validated by the full cross-validation method while the models for ascorbic acid
and sodium ascorbate assay in tablets were validated by the test-validation method. The
model with the highest predictive potential was selected according to conventional crite-
ria: low root mean square error of cross validation (RMSECV), low root mean square er-
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Table II. Composition of the calibration set, according to a 25 experimental design
Code X1 X2 Code X1 X2
N1 82.4 72.0 N15 123.6 90.0
N2 92.7 72.0 N16 82.4 99.0
N3 103.0 72.0 N17 92.7 99.0
N4 113.3 72.0 N18 103.0 99.0
N5 123.6 72.0 N19c 113.3 99.0
N6 82.4 81.0 N20 123.6 99.0
N7a 92.7 81.0 N21 82.4 108.0
N8 103.0 81.0 N22 92.7 108.0
N9 113.3 81.0 N23 103.8 108.0
N10 123.6 81.0 N24 113.3 108.0
N11 82.4 90.0 N25 123.6 108.0
N12 92.7 90.0 N26 103.0 90.0
N13b 103.0 90.0 N27 103.0 90.0
N14 113.3 90.0 N28 103.0 90.0
X1 – amount of ascorbic acid (mg per tablet); X2 – amount of sodium ascorbate (mg per tablet)
a Level 1 of validation samples (X1 = 90 %; X2 = 90 %);
b Level 2 of validation samples (X1 = 100 %; X2 = 100 %);
c Level 3 of validation samples (X1 = 110 %; X2 = 110 %).
ror of estimation (RMSEE), high coefficient of determination (R2), small number of PLS
factors, and low bias (14).
RESULTS AND DISCUSSION
Ascorbic acid and sodium ascorbate assay in powder blends for tableting:
development of models and validation
Twenty eight powder blends containing both ascorbic acid and sodium ascorbate
and a NIR-chemometric method to simultaneously and directly quantify the two com-
ponents was developed and validated.
Model development for API assay consisted of checking different combinations of
spectrum pretreatments in association with different selected spectrum regions. PLS re-
gression was performed with the calibration set and cross-validation was carried out for
model validation. The first step in model development was to investigate eleven pre-
-processing methods [models (a)-(k), Table III]. This investigation and the selection of
the model with the highest predictive potential were mainly based upon the choice of
the number of factors (main components), and calculation of the root mean square error
of cross validation (RMSECV), root mean square error of estimation (RMSEE), bias and
R2 (15). The models studied for ascorbic acid and sodium ascorbate assay in powder
blends and their most important characteristics are given in Table III.
The best results obtained after examining different spectral regions were for the mo-
dels created using the spectral region 10000–4133 cm–1 for ascorbic acid and 10000–4480
cm–1 for sodium ascorbate. Among the models presented in Table III, it can be seen that
for ascorbic acid, model (j) has better prediction ability than other models. The (j) model
has higher values for R2 and lower values for RMSECV and bias than other models, no-
tably models (g), (h) and (k). At the same time, it can be seen also in Table III, that for so-
dium ascorbate, model (h) is the model with a better prediction ability. Based on the
mentioned predictive ability criteria (low RMSEC, high R2, low number of PLS factors
and low bias), model (j) was selected as the best fitting model for the ascorbic acid assay
and model (h) was selected as the best fitting model for the sodium ascorbate assay.
The predictive ability of the chosen models was checked on independent samples
during the method validation step. Accuracy, precision (repeatability and intermediate
precision), linearity and specific range of application were the validation parameters.
Validation was performed according to the strategy proposed by Hubert et al. (16, 17).
This approach uses tolerance intervals as statistical methodology, which allows predict-
ing a region of concentrations where each future result has a probability to be defined by
the analyst (18). For validation purposes, independent batches comprising 4 replicates of
powder blends for tabletting at 3 different active levels of APIs (90, 100, and 110 %, m/m,
formulations N7, N13, N23) were prepared and analyzed on 3 different days, resulting
in a total of 36 samples. The accuracy profile has the advantage of taking into account
the total error, which is the sum of trueness (systematic error) and precision (random er-
ror) (16, 17).
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The validation criteria of the methods developed for ascorbic acid and sodium as-
corbate quantitative analysis in powder blends for tableting are given in Table IV. The
trueness of the method was evaluated by calculating recovery. The values obtained for
recovery were satisfactory for both APIs at all three concentration levels tested, all val-
ues being included in the range of 98.8 to 101.7 % (Table IV). The precision of the meth-
ods was evaluated by calculating repeatability at the three concentration levels (Table
IV). For ascorbic acid, the RSD repeatability ranged from 1.5 to 2.0 %, and for sodium
ascorbate, it was 1.2–1.9 %.
Fig. 1a shows the accuracy profile for the ascorbic acid assay in powder blends for
tableting, which is based on the validation results obtained with the developed NIR (j)
model, FD followed by SNV spectra pretreatments, in the spectral region 10000–4133
cm–1. Similarly, the accuracy profile for the sodium ascorbate assay in powder blends for
tableting was built using validation results obtained with the developed NIR (h) model,
SD spectra pretreatments, in the spectral region 10000–4480 cm–1 (Fig. 1b). As shown in
Fig. 1a and in Table IV, accuracy of the method for ascorbic acid in powder blends is
good, as the b-expectation tolerance limits do not exceed the ±5 % acceptance limits. The
largest relative tolerance limits were ± 5.0 %, for the lowest ascorbic acid content of pow-
378
I. Tomut¸ah et al.: Quantification of ascorbic acid and sodium ascorbate in powder blends for tableting and in vitamin C chewable
tablets by NIR-chemometry, Acta Pharm. 63 (2013) 373–384.
Table III. Type of spectral pre-treatment, R2, spectral range selected, number of PLS factors and
RMSECV of different models for ascorbic acid and sodium ascorbate assays in powder blends for
tableting
Model (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k)








Spectral range selected (cm–1) 10000–4133
Number of PLS factors 10 10 9 9 9 9 10 8 10 10 10
R2 90.58 91.38 92.61 93.97 92.62 93.92 94.33 95.98 94.61 96.75 95.49
RMSECV 0.687 0.664 0.612 0.559 0.633 0.561 0.540 0.452 0.525 0.396 0.478
Bias (%) 0.011 0.008 0.016 0.010 0.019 0.013 0.004 0.007 0.004 0.004 0.016
Sodium ascorbate
Spectral range selected (cm–1) 10000–4480
Number of PLS factors 10 9 10 10 9 10 10 10 10 10 10
R2 91.29 91.7 94.18 94.62 94.69 94.21 97.13 98.19 97.65 97.81 97.34
RMSECV 0.528 0.516 0.428 0.408 0.407 0.427 0.300 0.242 0.268 0.262 0.290
Bias (%) 0.017 0.007 0.003 0.005 0.021 0.004 0.018 0.009 0.017 0.017 0.014
No spectral pre-treatment.
COE – constant offset elimination, SLS – straight line subtraction, SNV – standard normal variate, MMN – mi-
nim-maxim normalization, MSC – multiplicative scatter correction, FD – first derivative, SD – second derivative,
FS+SLS–first derivative followed by straight line subtraction, FD+SVN – first derivative followed by standard
normal variate, FD+MSC – first derivative followed by multiplicative scatter correction.
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15.14 100.0 2.0 [–5.0, 5.0] [14.4, 15.9]
16.83 99.5 1.5 [–4.7, 3.8] [16.0, 17.5]
18.51 101.7 1.6 [–3.3, 4.7] [17.9, 19.4]
Sodium ascorbate
12.06 100.5 1.9 [–4.6, 5.6] [11.5, 12.7]
13.30 99.7 1.7 [–5.0, 4.4] [12.7, 13.9]
14.49 98.8 1.2 [–5.0, 2.6] [13.9, 15.0]
Fig. 1. Accuracy profile of the NIR methods for: a) ascorbic acid, b) sodium ascorbate assay in pow-
der blend for tableting, c) ascorbic acid and d) sodium ascorbate assay in tablets. The full line is rela-
tive bias, dashed lines are b-expectation tolerance limits (b = 95 %) and dotted curves are accep-
tance limits (±5 %).
a) b)
c) d)
der blends in validation batches. Similarly, the accuracy of the method for sodium ascor-
bate in powder blends seems quite good; the b-expectation tolerance limits exceeded
only slightly the ±5 % acceptance limits (Fig. 1b and Table IV). The largest relative toler-
ance limits were –5.0 % for the highest sodium ascorbate content and 5.6 %, for the low-
est sodium ascorbate content of powder blends in validation batches. Accuracy profiles
included in the ±5 % limits give enough confidence for the quality and reliability of the
results obtained by the developed NIR-chemometric methods (19).
The linear profile of the prediction models is shown in Figs. 2a and b. The linear
model was obtained by plotting calculated concentrations of the validation samples as a
function of introduced concentrations. Dashed limits correspond to the accuracy profile
and dotted curves represent the acceptance limits at ±5 % expressed in concentration
units. The linearity profile is within or close to the acceptance limits, the R2 value is hig-
her than 0.95 and the slope is very close to 1, confirming the linearity of the models for
ascorbic acid and sodium ascorbate assays in powder blends for tableting.
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Fig. 2. Linear profile of the NIR methods for: a) ascorbic acid, b) sodium ascorbate assay in powder
blend for tableting, c) ascorbic acid and d) sodium ascorbate assays in tablets. Dashed limits corre-
spond to the accuracy profile and dotted curves represent acceptance limits at ±5 %. Full line is the
identity line, y = x.
a) b)
c) d)
Ascorbic acid and sodium ascorbate assay in vitamin C chewable tablets:
development of models and validation
The other aim of our research was to develop a NIR-chemometric method suitable
for direct quantification of ascorbic acid and sodium ascorbate in tablets. For this pur-
pose, a protocol consisting of preparing and analyzing 28 of tablet formulations was fol-
lowed. Practically, the powder blends used for the development and validation of NIR
chemometric methods in powder blends for tableting were compressed into vitamin C
chewable tablets with a total mass of 600 mg per tablet. The same protocol and method-
ology as previously described for the development and validation of NIR chemometric
methods to simultaneously and directly quantify ascorbic acid and sodium ascorbate in
powder blends for tableting was followed for tablets.
Table V shows the main characteristics of the investigated models for ascorbic acid
and sodium ascorbate assays in tablets.
Based on the analysis of different spectral regions, the models generated with the
use of spectral region 8850–4070 cm–1 for both ascorbic acid and sodium ascorbate sho-
wed the best results. It can be seen from Table V that for ascorbic acid (j) model is better
than other models in terms of prediction. The (j) model has higher R2 values and lower
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Table V. Type of spectral pre-treatment, R2, spectral range selected, number of PLS factors, RMSEP
of different models for ascorbic acid and sodium ascorbate assays in tablets
Model (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k)








Spectral range selected (cm–1) 8850–4070
Number of PLS factors 8 8 8 7 8 8 10 9 10 10 10
R2 82.75 84.08 85.31 84.49 86.55 86.19 92.16 85.06 91.81 95.31 94.95
RMSEP 7.10 6.92 6.76 6.87 6.72 6.64 5.74 6.79 5.80 5.21 5.28
Bias (%) –0.541 –0.551 –0.478 –0.631 –1.22 –1.12 –0.14 0.24 –0.109 –0.097 –0.15
Sodium ascorbate
Spectral range selected (cm–1) 8850–4070
Number of PLS factors 9 10 10 9 9 9 9 8 9 8 8
R2 87.50 95.37 95.49 93.71 93.85 93.68 95.69 93.50 96.18 95.14 94.87
RMSEP 3.87 3.40 3.38 3.68 3.66 3.68 3.34 3.71 3.25 3.44 3.49
Bias (%) 0.127 –2.68 –0.201 –0.255 –0.409 –0.27 –0.36 –0.46 –0.262 –0.327 –0.386
No spectral pre-treatment.
COE – constant offset elimination, SLS – straight line subtraction, SNV – standard normal variate, MMN – mi-
nim-maxim normalization, MSC – multiplicative scatter correction, FD – first derivative, SD – second derivative,
FS+SLS – first derivative followed by straight line subtraction, FD+SVN – first derivative followed by standard
normal variate, FD+MSC – first derivative followed by multiplicative scatter correction.
values for RMSEP and bias than other models, especially (i) and (k) models. Regarding
sodium ascorbate, the (i) models prediction ability is better than any one of other mod-
els presented in Table V. On these grounds, the best fitting model chosen for the ascorbic
acid assay in tablets was model (j) with FD followed by SNV pre-treatment and model
(i) with FD followed by SLS pre-treatment was chosen as the most suitable model for the
sodium ascorbate assay in tablets.
Table VI shows validation criteria of the developed methods for ascorbic acid and
sodium ascorbate assays in tablets. Recovery had satisfactory values at all three concen-
tration levels for both APIs, the lowest value being 98.9 % and the highest 101.5 % (Table
VI). The precision of the methods was evaluated by calculating repeatability at the three
concentration levels used. Repeatability was good for all studied samples, parameters
had satisfactory values at all concentration levels for both APIs, ascorbic acid and so-
dium ascorbate (Table VI). RSD ranged from 1.6–1.9 % for ascorbic acid and 1.7–2.1 %
for Na-ascorbate.
Accuracy profiles for ascorbic acid and sodium ascorbate assays in tablets are given
in Figs. 1c and d, respectively. The accuracy profile for the ascorbic acid assay is based
on the validation results obtained with the NIR (j) model, FD followed by SNV spectra
pretreatments, in the spectral region 8850–4070 cm–1, while the accuracy profile for the
sodium ascorbate assay is based on the validation results obtained with the NIR (i) mo-
del, with FD followed by SLS spectra pretreatments, in the same spectral region. Since
b-expectation tolerance limits are maintained within ±5 % acceptance limits, the accu-
racy of the method for the ascorbic acid assay in tablets is considered good (Fig. 1c and
Table VI. The largest relative tolerance limits were –4.9 % for the medium ascorbic acid
content and 4.8 % for the highest ascorbic acid content of tablets in validation batches.
Similarly to the accuracy of the method for sodium ascorbate assay tablets is rather
good, the ±5 % (19) acceptance limits being only slightly exceeded (Fig. 1d) and Table
VI). The largest relative tolerance limits were –5.2 % for the highest sodium ascorbate
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91.85 101.5 1.6 [–1.8, 4.7] [90.2, 96.2]
100.94 99.3 1.8 [–4.9, 3.4] [96.0, 104.4]
111.03 100.4 1.9 [–4.0, 4.8] [106.5, 116.3]
Sodium ascorbatea
71.01 100.4 1.8 [–3.7, 4.6] [68.3, 74.3]
79.01 98.9 1.7 [–4.1, 3.8] [75.8, 82.0]
84.50 99.5 2.1 [–5.2, 4.1] [80.1, 87.9]
a Expressed on ascorbic acid equivalence basis.
content and 4.6 % for the lowest sodium ascorbate content of tablets in validation bat-
ches.
Figs. 2c and d represent linear profiles of the prediction models. Again, the linearity
profile is within the acceptance limits, the R2 value is higher than 0.95 and the slope is
very close to 1. This confirming the linearity of the models for ascorbic acid and sodium
ascorbate assays in tablets.
CONCLUSIONS
According to the data presented, the NIR-chemometric methods using the (j) model
for ascorbic acid and the (i) model for sodium ascorbate have good reproducibility and
satisfactory accuracy and linearity profiles. After analyzing the statistical parameters, it
can be concluded that both NIR-chemometric methods are linear and sufficiently precise
and accurate for simultaneous and direct quantification of the two components (ascorbic
acid and sodium ascorbate) in powder blends for tableting, and in chewable tablets.
In conclusion, the overall results of this paper indicate that near infrared spectros-
copy methods are appropriate and advantageous for directly predicting, without any
sample preparation, of ascorbic acid and sodium ascorbate in powder blends for tab-
leting and in vitamin C chewable tablets. Such rapid NIR-chemometric methods can be
used for on-line, in-line or at-line monitoring of the manufacturing process of vitamin C
chewable tablets and are helpful in achieving the goals of the process analytical technolo-
gy concept.
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